Immune suppression in the early stage of COVID-19 disease.
Wenmin TianNan ZhangRonghua JinYingmei FengSiyuan WangShuaixin GaoRuqin GaoGuizhen WuDi TianWenjie TanYang ChenGeorge Fu GaoCatherine C L WongPublished in: Nature communications (2020)
The outbreak of COVID-19 has become a worldwide pandemic. The pathogenesis of this infectious disease and how it differs from other drivers of pneumonia is unclear. Here we analyze urine samples from COVID-19 infection cases, healthy donors and non-COVID-19 pneumonia cases using quantitative proteomics. The molecular changes suggest that immunosuppression and tight junction impairment occur in the early stage of COVID-19 infection. Further subgrouping of COVID-19 patients into moderate and severe types shows that an activated immune response emerges in severely affected patients. We propose a two-stage mechanism of pathogenesis for this unusual viral infection. Our data advance our understanding of the clinical features of COVID-19 infections and provide a resource for future mechanistic and therapeutics studies.
Keyphrases
- sars cov
- coronavirus disease
- early stage
- immune response
- respiratory syndrome coronavirus
- end stage renal disease
- infectious diseases
- chronic kidney disease
- ejection fraction
- prognostic factors
- electronic health record
- blood brain barrier
- mass spectrometry
- high resolution
- big data
- squamous cell carcinoma
- high intensity
- lymph node
- dendritic cells
- current status
- inflammatory response
- respiratory failure
- rectal cancer
- mechanical ventilation
- data analysis
- peritoneal dialysis
- case control